Lasa Supergenerics Limited (NSE:LASA)

Market Cap	400.31M -54.6%
Revenue (ttm)	669.61M -47.8%
Net Income	-442.17M
EPS	-9.07
Shares Out	50.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,058
Average Volume	17,024
Open	7.73
Previous Close	7.99
Day's Range	7.73 - 8.38
52-Week Range	5.67 - 19.00
Beta	0.60
RSI	50.77
Earnings Date	May 29, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 66
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LASA

Financial Performance

In fiscal year 2025, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.20% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2024.